The narrower loss and cash runway into 2029 remove near-term financing risk. The key binary catalyst is MAIA-ovarian data in Q1 2027; positive results could validate COM701 and unlock significant value. Monitor AstraZeneca's rilvegostomig Phase 3 readout in H2 2027 for milestone potential.
Drug in focus
CGEN drug pipeline →COM701
◆ Mixed Named in this 6-K- Impact
- Phase
- Phase 1/2
- Time to market
- At least 3-5 years. COM701 is in Phase 1/2 (MAIA trial); even with positive interim data in Q1 2027, a registrational Phase 3 trial and FDA review would follow, putting potential approval in the 2029-2031 timeframe.
- Next catalyst
- None dated
What to watchThe next hard catalyst for COM701 is the MAIA-ovarian interim PFS analysis expected by Q1 2027, roughly 4-6 months out. Positive data could drive a significant re-rating given the strong analyst consensus (10 Buy/Strong Buy vs 1 Hold) and ~41% implied upside to the $4.60 mean price target. Negative data would be a major setback for Compugen's wholly-owned pipeline. Monitor for any pre-announcements or delays.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 9 $2.14entry
- T+1 · 7d ago −2.34%α −1.97% · $2.09
- T+5 · 20h ago −4.67%α −2.98% · $2.04
- T+20 · in 21d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Compugen reported Q3 2026 net loss of $5.8M ($0.06 per share), narrower than the $7.0M loss in Q3 2025, on revenue of $3.8M (up from $1.9M). The EPS of -$0.06 beat the consensus estimate of -$0.09. Cash of $117.5M is expected to fund operations into 2029. Key pipeline catalysts include MAIA-ovarian results by end of Q1 2027 and Phase 3 rilvegostomig data from AstraZeneca in H2 2027.
Key Financial Metrics
Key Facts
- Q3 2026 net loss of $5.8M ($0.06 per share) vs $7.0M ($0.07) in Q3 2025
- Revenue of $3.8M vs $1.9M in Q3 2025, driven by Gilead license revenue recognition
- Cash and equivalents of $117.5M as of Sep 30, 2026; runway into 2029
- MAIA-ovarian trial (COM701) fully enrolled; results expected by end of Q1 2027
- AstraZeneca Phase 3 rilvegostomig data from ARTEMIDE-Biliary01 anticipated H2 2027
- GS-0321 (licensed to Gilead) Phase 1 dose-escalation trial advancing
- Up to $195M in additional milestones from AstraZeneca; up to $758M from Gilead
Financial Impact
Net loss improved by $1.2M YoY; revenue doubled to $3.8M; cash position $117.5M
Risk Factors
- MAIA-ovarian trial may fail to show statistically significant PFS benefit
- Reliance on partner AstraZeneca and Gilead for development and commercialization
- No approved products; pre-revenue stage with ongoing operating losses
- Israel-based operations subject to geopolitical risk
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001178913-26-005086 |
| Document: zk2636367.htm | 0001178913-26-005086 |
| Document: 0001178913-26-005086-index-headers.html | 0001178913-26-005086 |
| Document: 0001178913-26-005086-index.html | 0001178913-26-005086 |
| Document: 0001178913-26-005086.txt | 0001178913-26-005086 |
| Earnings Context (Synthetic; results releases only) | 0001178913-26-005086 |
Track record
9 reports on CGEN
Filters
- Nov 9, 20267d ago 6-K Neutral 4/10 Viewing Entry $2.14 Now $2.04 −4.67% settles Dec 8
- Aug 3, 202615w ago 6-K Neutral 2/10 Entry $2.38 to $2.56 Now $2.04 −14.29% ▲ +7.56% +6.33% vs SPY
- Aug 3, 202615w ago 6-K Neutral 4/10 Entry $2.38 to $2.56 Now $2.04 −14.29% ▲ +7.56% +6.33% vs SPY
- Jun 9, 202623w ago EFFECT Neutral 3/10 Entry $2.02 to $2.39 Now $2.04 +0.99% ▲ +18.32% +16.87% vs SPY
- May 18, 202626w ago 6-K Neutral 4/10 Entry $2.86 to $2.03 Now $2.04 −28.67% ▼ −29.02% −30.60% vs SPY
- Apr 24, 202629w ago Insider Cluster Neutral 2/10 Entry $3.10 to $2.61 Now $2.04 −34.19% ▼ −15.81% −19.83% vs SPY
- Apr 14, 202631w ago Insider Cluster Neutral 2/10 Entry $2.88 to $2.87 Now $2.04 −29.17% ▼ −0.35% −6.64% vs SPY
- Apr 13, 202631w ago 144 Neutral 3/10 Entry $2.76 to $2.87 Now $2.04 −26.09% ▲ +3.99% −3.74% vs SPY
- Mar 26, 202633w ago Insider Cluster Neutral 3/10 Entry $2.06 to $3.10 Now $2.04 −0.97% ▲ +50.49% +39.82% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers